Clinical Trial

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

Name: A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer — clinical trial record (NCT06319820)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MoonRISe-1

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.

Trial Details

NCT Number	NCT06319820
Lead Sponsor	Janssen Research & Development, LLC
Conditions	Non-Muscle Invasive Bladder Neoplasms
Enrollment	641 participants
Start Date	2024-04-18
Primary Completion	2028-06-28 (estimated)
Study Completion	2032-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-06